Hormonal signaling in prostatic hyperplasia and neoplasia

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 10, 1999, Pages 3463-3468

  Marcelli, Marco ^a   Cunningham, Glenn R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTROGEN; SEX HORMONE; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER MORTALITY; GENE MUTATION; HORMONAL THERAPY; HORMONE DEFICIENCY; HUMAN; MALE; NOTE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RECEPTOR GENE;

EID: 0033304531     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.10.3463     Document Type: Note

References (40)

1. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: Results of community based studies in 2 countries
2. Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994
3. Latent prostatic cancer in a consecutive autopsy series
4. Cancer statistics 1999
5. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986
6. Clinical and biochemical parameters of androgen action in normal healthy Caucasian vs. Chinese subjects
7. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects
8. Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men?
9. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia
10. Androgens in serum and the risk of prostate cancer: A nested case-control study from the Janus serum bank in Norway
11. Prospective study of sex hormone levels and risk of prostate cancer: A prospective, population-based study of androstenedione, estrogens, and prostatic cancer
12. Molecular genetics and epidemiology of prostate carcinoma
13. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy
14. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: Possible pathogenetic relevance for the (CAG)n-expanded neuronopathies
15. Transcriptional activation and transient expression of the human androgen receptor
16. Reduced androgen receptor gene expression with first exon CAG repeat expansion
17. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia
18. Evaluation of average life span of epithelial and stromal cells of human prostate by superoxide dismutase activity
19. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia
20. Kinetic analysis of steroid 5α-reductase activity at neutral pH in benign prostatic hyperplastic tissue: Evidence for type I isozyme activity in the human prostate
21. Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal
22. Effect of aging on endogenous level of 5 α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate
23. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH)
24. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia
25. Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs
26. Generation and reproductive phenotypes of mice lacking estrogen receptor β
27. Regulation of prostatic growth and function by peptide growth factors
28. Etiology and disease process of benign prostatic hyperplasia
29. Stem cell features of benign and malignant prostate epithelial cells
30. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase
31. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility
32. Steroid receptor in prostate cancer development
33. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men
34. The effect of finasteride in men with benign prostatic hyperplasia
35. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia
36. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia
37. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
38. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
39. Mutations of the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
40. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for the treatment of prostate cancer